Corporate Update
JEAN-CHRISTOPHE MONTIGNY, CFO MEDIAN TECHNOLOGIES
MAY 2024
Applying AI and computer vision, we help conquer cancer and other life-threatening diseases by extracting powerful clinical insights from medical images.
Our people | 260+ highly qualified professionals in the |
US, Europe and China, 25+ nationalities | |
(As of Dec. 31, 2023). | |
Our growth | Powered by proprietary AI, computer |
vision and signal processing technologies, | |
strong KOL connections, and medical, | |
scientific, technology partnerships. | |
With eyonis , our AI/ML tech-based | |
suite of software as medical devices | |
(SaMD), we help enable clinicians to | |
diagnose patients earlier. | |
Imaging | Our iCRO imaging solutions and advanced |
Lab | Imaging Lab offer help our 80+ |
biopharma clients drive their oncology | |
clinical studies toward successful | |
approval, using AI-driven image insights. | |
The Global Cancer Burden
Imaging AI will have the biggest impact ever on cancer care
3 | mediantechnologies.com | May 2024 | Financial Conferences | Paris, France |
Facts & Trends about Cancer
Financial burden of
1 cancer in the US was $210bn in 2020 and projected to exceed $245bn by 2030 [1].
The cost for bringing a
4 cancer drug to market is $2.7Bn [2] during 12 years. With AI it could be a fraction of the cost & time
97% of cancer care
2 money goes for treatment of sick patients vs 3% for preventive care.
5 | The cost of developing a |
new AI based imaging |
diagnostic test for cancer is approx. $40m.
3
6
Most Stage 1 cancer can be cured and can now be identified with Imaging AI.
Most cancer drugs could become curative through personalized treatments. Viral Therapy, vaccine & immune therapy
Sources: | |||
[1] | American Association for Cancer Research | ||
4 | mediantechnologies.com | May 2024 | Financial Conferences | Paris, France | [2] | Deloitte Report - January 2023 |
US Cancer Death Rates Evolution over the Long-run
Early diagnosis and lifestyles changes have the biggest impact on cancer death rates:
• Lung and stomach cancer death rates decrease, driven by lifestyles changes.
• Prostate, colorectal and breast cancer rates decrease, driven by early diagnosis and screening programs.
5 mediantechnologies.com | May 2024 | Financial Conferences | Paris, France
AI Breakthroughs Applied to Medical Imaging Mark the Beginning of a New Era for Cancer Management
Applying AI and computer vision technologies help conquer cancer by extracting powerful clinical insights from medical images.
1| | 2| | 3| | Guide health |
professionals in | |||
Diagnose | their clinical | ||
cancer earlier | Personalize | ||
decision-making | |||
and more | treatments | ||
with data- | |||
accurately | driven clinical |
insights |
6 | mediantechnologies.com | May 2024 | Financial Conferences | Paris, France |
Median Technologies Leverages AI Technologies to Bring More Value to Medical Images all along the Patient Journey
Adding more | Generating more | Providing more |
AI-driven data | ||
value to oncology | accurate | |
for oncology | ||
trials | AI-driven diagnosis | |
drug development | ||
• | Extract drug efficacy data | • | Select early-stage patient | • | Develop noninvasive, early- | ||
• | Streamline the clinical | • | Discover predictive | stage diagnostic solutions | |||
process | imaging biomarkers | • | Market SaMDs for routine | ||||
clinical use | |||||||
• | Develop companion diagnostics |
7 | mediantechnologies.com | May 2024 | Financial Conferences | Paris, France |
Shifting the Early Diagnostic Paradigm with Artificial Intelligence
We are developing the next generation AI/ML tech-based Software as Medical Devices (SaMD) to help detect, diagnose and monitor early-stage cancer patients.
8 | mediantechnologies.com | May 2024 | Financial Conferences | Paris, France |
eyonis Integration in the Radiology Workflow
9 | mediantechnologies.com | May 2024 | Financial Conferences | Paris, France |
Lung Cancer Screening
I-ELCAP study showed a 92% survival rate at 15y when diagnosed at stage 1 vs. 5% for stage 4 (1) Lack of diagnosis accuracy is a major hurdle to screening adherence & programs implementation
Facts & Figures
- 1st cancer killer worldwide - 18% of all 2020 cancer deaths, equal to colorectal & liver cancers combined (2)
-
1.8M deaths in 2020, 2.4M projected in
2030 (2) - A new CPT reimbursement code of $650 for quantitative CT tissue characterization in the US
- The Lung Cancer Screening TAM is $10- 20bn for the US & EU and could double with Asia
- Rising frequency among never-smokers, 20% in the US & UK (3)
- Only 870K screenings performed in the US in 2021 - 6% compliance (4)
10 mediantechnologies.com | May 2024 | Financial Conferences | Paris, France
Target Population
LCS Programs | Target population | |
US | Implemented - USPSTF | 19M (USPSTF, 2023 |
guidelines | recommendations) | |
Implemented in Croatia | ||
Europe | & Poland - Starting in UK | EU T5: 22M (Est.) |
- Developing in | ||
IT/FR/GE/SP/NL/SW | ||
Implemented in SK | ||
Asia | nationally & China | ASIA T3: 100M |
regionally - Japan/Taiwan | (Est.) | |
study phase | ||
Sources:
- https://www.redjournal.org/article/S0360-3016(19)30110-5/fulltext
- Cancer Tomorrow, IARC, Global Cancer Observatory 2020 - WHO
- https://www.lungambitionalliance.com/our-initiatives/lung-cancer-screening-the-cost-of-inaction.htm
- https://nrdrsupport.acr.org/support/solutions/articles/11000093991-lcsr-state-reports
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Median Technologies SA published this content on 16 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 May 2024 20:45:49 UTC.